Antiplatelet (aspirin) therapy as a new option in the treatment of vasculogenic erectile dysfunction: a prospective randomized double-blind placebo-controlled study
- 283 Downloads
To investigate the efficiency of antiplatelet (aspirin) therapy in vasculogenic erectile dysfunction (VED) patients with a high mean platelet volume.
A total of 184 patients diagnosed with VED between the ages of 18 and 76 were randomly divided into two groups and treated for 6 weeks [group 1: 120 patients (mean age 48.3), aspirin 100 mg/day; group 2: 64 patients (mean age 47.7), placebo 100 mg/day]. The changes from baseline to end point in erectile function scores on the International Index of Erectile Function (IIEF-EF) and the number of patients who answered “yes” to questions 2 and 3 of the sexual encounter profile (SEP) were compared statistically.
The mean baseline IIEF-EF scores in groups 1 and 2 were 14.1 ± 4.9 and 14.3 ± 5.2, respectively (p = 0.7966), the number of patients who answered “yes” to SEP-2 was 62 (51.6%) in group 1 and 32 (50%) in group 2 (p = 0.8366), and the number of patients who answered “yes” to SEP-3 was 38 (31.6%) in group 1 and 20 (31.2%) in group 2 (p = 0.9557). In the aspirin group, the changes from baseline to end point in the IIEF-EF, SEP-2, and SEP-3 scores were 7.2, 36.6, and 46.6%, respectively. In the placebo group, these changes were 2.0, 9.4, and 12.5%, respectively. When compared with the placebo group, aspirin-treated subjects showed a significant improvement in all three efficacy measures (p < 0.0001).
100 mg of aspirin administered once a day significantly improved EF in men with VED.
KeywordsAspirin Antiplatelet Antithrombocytic Erectile dysfunction Treatment
Coronary artery disease
Cyclic adenylate monophosphate
Cyclic guanylate monophosphate
Prostaglandin H synthase
International Index of Erectile Function
Mean platelet volume
Peak systolic velocity
Peripheric artery disease
Sexual encounter profile
Vasculogenic erectile dysfunction
Compliance with ethical standards
Conflict of interest
Both authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the Declaration of Helsinki (1964) and its later amendments or comparable ethical standards.
Human and animal rights statement
This article does not contain any studies with animals performed by any of the authors.
Informed consent was obtained from all individual participants included in the study.
- 8.Çayan S, Kendirci M, Yaman Ö et al (2017) Prevalence of erectile dysfunction in men over 40 years of age in Turkey: results from the Turkish Society of Andrology Male Sexual Health Study Group. Turk J Urol 43(2):122–129. https://doi.org/10.5152/tud.2017.24886 (Epub 2017 Jun 1) CrossRefPubMedPubMedCentralGoogle Scholar
- 18.La Vignera S, Vicari E, Condorelli RA, Di Pino L, Calogero AE (2012) Arterial erectile dysfunction: reliability of penile Doppler evaluation integrated with serum concentrations of late endothelial progenitor cells and endothelial microparticles. J Androl 33(3):412–419. https://doi.org/10.2164/jandrol.111.014712 (Epub 2011 Aug 25) CrossRefPubMedGoogle Scholar